Jazz Pharmaceuticals (J7Z) AI Stock Analysis

3 Followers

Jazz Pharmaceuticals

(XETRA:J7Z)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong cash generationRobust operating and free cash flow gives Jazz internal funding capacity for product launches, pipeline development, acquisitions and debt management. Because cash generation has generally tracked reported earnings, it also supports the quality and durability of the company’s operating model.

Negative Factors

Elevated leverageElevated debt reduces financial flexibility even though leverage has improved from 2022 levels. Interest obligations and refinancing needs can constrain investment choices, particularly if product growth slows or Jazz must fund additional acquisitions and development programs.

Jazz Pharmaceuticals (J7Z) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 15.93B
Dividend Yield: ―
Average Volume (3M): 24
Price to Earnings (P/E): 69.3
Beta (1Y): 0.45
Revenue Growth: 8.06%
EPS Growth: ―
Country: Germany
Employees: 2,890
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Jazz Pharmaceuticals Business Overview & Revenue Model

Company Description

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopat...

Jazz Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 02, 2026(Q3-2026)|% Change Since:15.24%|Next Earnings Date:Mar 02, 2027

Earnings Call SentimentPositive

The call was strongly positive. Jazz reported record revenue, raised full-year revenue and gross-margin guidance, delivered strong growth across oncology and Xywav, and described an encouraging early launch for Ziihera supported by favorable clinical data and market access. The company also highlighted substantial cash generation, pipeline progress and the Actio acquisition. Offsetting factors included lower adjusted gross margin, a reported non-GAAP loss driven by the Actio acquired IPR&D charge, a measured near-term Modeyso revenue pace, and future competitive pressure for Zepzelca. The positive operating and strategic developments significantly outweighed the stated challenges.

Positive Updates

Record Quarterly Revenue and Raised Guidance

Third-quarter revenue reached a record $1.24 billion, up 10% year-over-year. The company raised and narrowed 2026 total revenue guidance to $4.775 billion to $4.85 billion, with the midpoint representing nearly 13% growth over 2025.

Negative Updates

Adjusted Gross Margin Declined Year-over-Year

Non-GAAP adjusted gross margin declined by 110 basis points year-over-year, primarily because of royalties on higher Modeyso and Zepzelca sales and technology transfers for manufacturing several products.

Company Guidance

For 2026, Jazz raised and narrowed total revenue guidance to a range of $4.775 billion to $4.85 billion, representing nearly 13% growth over 2025 at the midpoint; rare sleep revenue is now expected to be $2.125 billion to $2.175 billion, led by Xywav growth of low double digits to low teens, while non-GAAP gross margin guidance increased by 50 basis points to a range of 90.5% to 91.5%, non-GAAP effective tax rate guidance is a range of 19.5% to 21.5%, and share count guidance remains unchanged at 69 million to 70 million shares. Ziihera peak sales potential is a range of $3 billion to $5 billion, Modeyso has a $500 million peak expectation in the U.S., and Zepzelca is likely to face a future headwind in 2027.

Jazz Pharmaceuticals Risk Analysis

Jazz Pharmaceuticals disclosed 47 risk factors in its most recent earnings report. Jazz Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Jazz Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:J7Z against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NBIX	80Outperform	$17.12B	25.02	19.74%	―	37.98%	61.95%
HRMY	77Outperform	$1.97B	11.11	18.55%	―	19.79%	-4.89%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRAX	51Neutral	$9.44B	-27.00	-29.41%	―	-100.00%	0.75%
AXSM	47Neutral	$7.42B	-48.77	-189.73%	―	54.16%	34.51%
XENE	46Neutral	$4.07B	-8.96	-39.80%	―	-100.00%	-21.09%

* Healthcare Sector Average

Performance Comparison

DE:J7Z and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:J7Z	Jazz Pharmaceuticals	221.20	99.85	82.28%
NBIX	Neurocrine Biosciences	174.41	30.25	20.98%
XENE	Xenon Pharmaceuticals	42.10	2.06	5.14%
AXSM	Axsome Therapeutics Inc.	149.24	11.84	8.62%
HRMY	Harmony Biosciences Holdings, Inc.	34.22	-0.07	-0.20%
PRAX	Praxis Precision Medicines, Inc.	346.21	168.13	94.41%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Jazz Pharmaceuticals AI Stock Analysis